News

The study showed, however, that physicians can help solve the problem if they are willing to answer patient’s questions about the therapy’s efficacy and safety.

Dr. Elizabeth Garner speculates the FDA approval of RBX2660 for recurrent C difficile infection will pave the way for more restorative microbiome therapies.

The European Commission has approved their first dengue vaccine, Takeda’s TAK-003, as climate change and urbanization contribute to a worldwide rise in dengue incidence.

With an already overwhelming respiratory virus season with RSV and influenza, the hope is to prevent COVID-19 with these vaccines available to younger pediatric populations.

A deep dive into the number of deaths from COVID-19 and other causes reveals a significant disparity between the US and its peer nations.

Ferring Chief Scientific Officer Dr. Elizabeth Garner explains the FDA approval of recurrent C diff treatment RBX2660 provides more than a treatment option, it’s a promise of safety and standardization.

A clinician offers insight into what he sees in terms of these therapies and the need to get more information to those providers in the field as well as access to them.

A new study examining COVID-19 outcomes over time found evidence supporting the use of dexamethasone and raised concerns about using nonconcurrent controls in large platform trials.

COVID-19 hospital patients were prescribed 21.81% more antibiotics than patients without COVID-19. How did this affect their risk of coinfection?

With the proliferation of therapies for skin and soft tissue infections (SSTIs), a clinician discusses how providers can appropriately find the balance between these novel therapies, the existing treatment guidelines, and stewardship.

A new report finds veterans who took vitamin D supplements were less likely to get COVID-19 and less likely to die within 30 days of infection.

A clinician has a novel approach to patient conversations around this topic to determine if they want to assess if their penicillin allergies truly present a problem for treatment.

Today, Pfizer-BioNTech filed submitted an Emergency Use Authorization (EUA) to administer their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in children under 5 years of age.

Children as young as 12 can now receive tenofovir alafenamide for treatment of chronic hepatitis B virus infection with compensated liver disease, after the US Food and Drug Administration expanded the indication for the drug.

With major updates in HIV, C difficile, hepatitis, yeast infections, and skin and soft tissue infections, this week's Infectious Disease Update has something for everyone.

A germline-targeting HIV vaccine candidate elicited broadly neutralizing antibodies in 97% of recipients.

In episode 1 of this short video series, a clinician discusses what types of patients are best suited for inpatient or outpatient care for these infections.

Two patients at a hospital in Australia were administered Thin Film Freezing Voriconazole Inhalation Powder (TFF VORI), which showed treatment efficacy for both patients.

The investigational shot from Pfizer and Valneva demonstrated higher antibody levels in the three-dose vaccination schedule versus the two-dose vaccination schedule.

Ibrexafungerp tablets (Brexafemme) were already FDA approved to treat vulvovaginal candidiasis (VVC) and have now received a second indication for the reduction of recurrent VVC (yeast infection).

Tonight, the FDA announced that Rebyota (RBX2660) is the first approved fecal microbiota product, intended to prevent recurrent C difficile infection in adults.

Resistance to hepatitis C infection may be much greater than previously thought, according to new research by investigators at Trinity College Dublin that revealed associated biological factors.

Alternative strategies to increase immunogenicity of COVID-19 vaccines in immunosuppressed kidney transplant recipients are evaluated in clinical trial.

Takeda’s investigational dengue vaccine TAK-003 is currently under evaluation for preventing any dengue virus serotype in individuals 4-60 years old.

Priorix and M-M-R II are fully interchangeable vaccines to protect against measles, mumps, and rubella, the CDC’s Advisory Committee on Immunization Practices said.

The World Health Organization (WHO) made the announcement today.

Investigators looked at COVID-19 related hospitalizations in infants less than 6 months old who were unable to be vaccinated. The researchers used population-based surveillance for lab-confirmed COVID-19 hospitalizations.

A recent study by investigators at the University of Pittsburgh School of Medicine found few mild adverse events from monoclonal antibody treatment among pregnant people with COVID-19, but no difference in COVID-19 outcomes.

November is C difficile Awareness Month. We're recapping the most significant potential therapies and remaining challenges from the past month.

Dr. Teena Chopra discusses the global need to do more to prevent healthcare-associated infections like C difficile in vulnerable patient populations.